DUBLIN, Ireland, July 20, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2017.
Quarter 2 Results
Total revenues for Q2, 2017 were $25.4m compared to $26.3m in Q2, 2016.
